Arbutus Biopharma (ABUS) Current Assets (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Current Assets for 17 consecutive years, with $277.0 million the latest figure, recorded in Q1 2026.

• Quarterly Current Assets rose 137.15% year-over-year to $277.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $277.0 million (up 137.15% YoY) and the FY2025 annual result came in at $94.5 million, down 25.81% from the prior year.
• Current Assets improved to $277.0 million in Q1 2026 per ABUS's latest filing, from $94.5 million in the prior quarter.
• Over the last five years, Current Assets for ABUS reached as high as $277.0 million in Q1 2026 and fell as low as $94.5 million in Q4 2025.
• A 5-year average of $143.6 million and a median of $141.1 million in 2022 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2025 — Current Assets sank 30.43% — and 2026, when it surged 137.15%.
• Year by year, Current Assets stood at $151.1 million in 2022, then declined by 12.65% to $132.0 million in 2023, then declined by 3.57% to $127.3 million in 2024, then fell by 25.81% to $94.5 million in 2025, then jumped by 193.27% to $277.0 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $277.0 million, $94.5 million, and $97.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.